enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. 3 Drugs Approved, but Only 1 Matters - AOL

    www.aol.com/news/2012-08-06-3-drugs-approved-but...

    Regeneron Pharmaceuticals (NAS: REGN) has gained Food and Drug Administration approval of its third drug, Zaltrap, which treats metastatic colorectal cancer. Three approvals in four years is no ...

  3. Regeneron Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Regeneron_Pharmaceuticals

    Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...

  4. US FDA approves Regeneron's ultra-rare blood disease drug - AOL

    www.aol.com/news/us-fda-approves-regenerons...

    (Reuters) -Regeneron Pharmaceuticals said on Friday the U.S. health regulator approved its drug to treat a rare blood disease. The drug pozelimab, branded as Veopoz, would treat CHAPLE disease in ...

  5. US FDA approves two biosimilars for blockbuster eye drug Eylea

    www.aol.com/news/us-fda-approves-two-biosimilars...

    (Reuters) -The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the blockbuster ...

  6. Atoltivimab/maftivimab/odesivimab - Wikipedia

    en.wikipedia.org/wiki/Atoltivimab/maftivimab/...

    The FDA granted the approval of Inmazeb to Regeneron Pharmaceuticals with an indication for the treatment of infection caused by Zaire ebolavirus in October 2020. [ 2 ] [ 6 ] The drug has also received orphan drug designation from the European Medicines Agency .

  7. Odronextamab - Wikipedia

    en.wikipedia.org/wiki/Odronextamab

    [1] [2] It was developed by Regeneron Pharmaceuticals. [1] The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia (fever), anemia, thrombocytopenia, and diarrhea. [1] Odronextamab was approved for medical use in the European Union in August 2024. [1] [2]

  8. Regeneron's Eylea could return to growth after nod to high ...

    www.aol.com/news/regenerons-eylea-could-return...

    A longer dosing gap for the drug could help Regeneron take on rival Roche's Vabysmo and also help soften the blow from incoming cheaper copycat drugs, analysts said. Shares of Regeneron rose 1.7% ...

  9. US FDA declines to approve Regeneron's blood cancer therapy - AOL

    www.aol.com/news/us-fda-declines-approve...

    Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment. The ...